Going beyond CRISPR with 1 million edits per cell │ Dr. George Church

Posted on September 2nd 2022 (over 2 years)

The BDNF Protocol Guide

An essential checklist for cognitive longevity — filled with specific exercise, heat stress, and omega-3 protocols for boosting BDNF. Enter your email, and we'll deliver it straight to your inbox.

Your subscription could not be saved. Please try again.
Please check your email to confirm your subscription and get The BDNF Protocol Guide!

You'll also receive updates from Rhonda & FoundMyFitness

CRISPR-Cas9 is a system of gene editing that has revolutionized how scientists engineer cells over the past decade. Before CRISPR, homologous recombination and single-stranded DNA annealing proteins (SSAPs) enabled early gene editing, but what comes next? Deaminases, transposonases, and more sophisticated SSAPs are able to deliver gene therapies with more precision than CRISPR.

Multiplex editing allows geneticists to make multiple genome alterations at once. Using this amazing technology, humanized organs from large mammals like pigs will enable organ transplantation on demand instead of patients waiting for years for a donor. Base editing in humans may facilitate gene therapies that eliminate common diseases of aging such as high cholesterol. Unlike antibody treatments that target the PCSK9 protein (an important regulator of blood cholesterol levels), which are very expensive, base editing could deliver permanent protection from hypercholesterolemia with just one dose. In this clip, Dr. George Church shares insights on the future of gene therapies in healthcare.

Hear new content from Rhonda on The Aliquot, our member's only podcast

Listen in on our regularly curated interview segments called "Aliquots" released every week on our premium podcast The Aliquot. Aliquots come in two flavors: features and mashups.

  • Hours of deep dive on topics like fasting, sauna, child development surfaced from our enormous collection of members-only Q&A episodes.
  • Important conversational highlights from our interviews with extra commentary and value. Short but salient.